AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, and Thermo Fisher Scientific are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological processes—such as genetic engineering, cell therapy and molecular diagnostics—to develop medical treatments, diagnostics and other life-science innovations. Because these firms often spend years and large sums on research and clinical trials before earning revenue, their stock prices can be highly volatile. Investors are drawn by the potential for breakthrough therapies but must also weigh significant regulatory and clinical-trial risks. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV traded down $0.09 during mid-day trading on Friday, reaching $185.53. 11,606,785 shares of the stock were exchanged, compared to its average volume of 6,281,110. The company has a 50 day moving average price of $185.97 and a two-hundred day moving average price of $186.26. The stock has a market capitalization of $327.72 billion, a PE ratio of 77.30, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. AbbVie has a 1 year low of $156.20 and a 1 year high of $218.66.
Read Our Latest Research Report on ABBV
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
NYSE:DHR traded down $0.93 on Friday, hitting $189.54. The stock had a trading volume of 6,514,078 shares, compared to its average volume of 3,485,178. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70. The firm's fifty day simple moving average is $192.72 and its two-hundred day simple moving average is $213.78. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a market cap of $135.65 billion, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80.
Read Our Latest Research Report on DHR
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of VRTX stock traded down $4.08 during trading on Friday, hitting $443.01. The company's stock had a trading volume of 2,581,676 shares, compared to its average volume of 1,424,504. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a market cap of $113.76 billion, a PE ratio of -201.37, a P/E/G ratio of 2.11 and a beta of 0.51. The business has a fifty day moving average of $469.67 and a 200-day moving average of $461.14. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.
Read Our Latest Research Report on VRTX
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
COR traded up $0.80 during trading on Friday, hitting $291.49. 3,890,003 shares of the company traded hands, compared to its average volume of 1,547,026. The firm has a market cap of $56.50 billion, a P/E ratio of 41.46, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora has a one year low of $218.65 and a one year high of $309.35. The stock's fifty day moving average is $284.83 and its 200 day moving average is $258.55.
Read Our Latest Research Report on COR
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE:TMO traded down $1.34 during trading hours on Friday, reaching $402.41. The stock had a trading volume of 2,521,302 shares, compared to its average volume of 1,879,798. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market cap of $151.91 billion, a P/E ratio of 24.34, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific has a 12-month low of $390.50 and a 12-month high of $627.88. The stock has a 50 day simple moving average of $430.85 and a 200 day simple moving average of $500.06.
Read Our Latest Research Report on TMO
Recommended Stories
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
